Review of the recent at-risk-launches
Share this page:
Review of the recent at-risk-launches; Analysis of launching at-risk during trial or appeal; Examining New Guidance for Calculating Damages post an at-risk Launch; Damages calculation in view of AstraZeneca AB v. Apotex Corp.; Review of recent inequitable conduct cases impacting ANDA litigation post Therasense;
This website does not track your personal or demographic information, only anonymous usage statistics. To ensure that you are not tracked, we have blocked all embedded content from third party sources like YouTube and SlideShare. Click "Accept Cookies" to enable third-party content. To learn more about our cookie policy, click here.